In CRC mouse models, it was shown that TGF-β elevation in the tumor microenvironment confers resistance to anti-PD-1 therapy via inhibition of T-cell infiltration and decreased levels of type 1 T-helper cell phenotype (94). Here, TGFB1 is linked to colorectal carcinoma.